Literature DB >> 12902571

Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts.

C J N Lacey1, R L Goodall, G Ragnarson Tennvall, R Maw, G R Kinghorn, P G Fisk, S Barton, I Byren.   

Abstract

OBJECTIVES: To evaluate the efficacy and cost effectiveness of self applied podophyllotoxin 0.5% solution and podophyllotoxin 0.15% cream, compared to clinic applied 25% podophyllin in the treatment of genital warts over 4 weeks.
METHODS: We conducted a randomised controlled trial in 358 immunocompetent men and women with genital warts of 3 months' duration or less.
RESULTS: In the principal analysis both podophyllotoxin solution (OR 2.93, 95% CI 1.56 to 5.50) and podophyllotoxin cream (OR 1.97, 95% CI 1.04 to 3.70) were associated with significantly increased odds of remission of all warts compared to podophyllin. We performed two further analyses. When subjects defaulting from follow up were assumed to have been cured odds of remission of all warts were also significantly increased both for podophyllotoxin solution (OR 3.04, 95% CI 1.68 to 5.49) and for podophyllotoxin cream (OR 2.46, 95% CI 1.38 to 4.40). When subjects defaulting from follow up were assumed not to have been cured odds of remission of all warts were significantly increased for podophyllotoxin solution (OR 1.92, 95% CI 1.13 to 3.27), but not for podophyllotoxin cream (OR 1.17, 95% CI 0.69 to 2.00). Local side effects were seen in 24% of subjects, and recurrence of warts within 12 weeks of study entry in 43% of all initially cleared subjects, without statistically significant differences between the treatment groups. Direct, indirect, and total costs were similar across the three treatment groups. Podophyllotoxin solution was the most cost effective treatment, followed by podophyllotoxin cream, with podophyllin treatment being the least cost effective.
CONCLUSIONS: Self treatment of anogenital warts with podophyllotoxin showed greater efficacy and cost effectiveness than clinic based treatment with podophyllin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902571      PMCID: PMC1744726          DOI: 10.1136/sti.79.4.270

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  19 in total

1.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

2.  Cost-of-illness studies: a major headache?

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

3.  Economic analysis alongside clinical trials. Revisiting the methodological issues.

Authors:  M F Drummond; L Davies
Journal:  Int J Technol Assess Health Care       Date:  1991       Impact factor: 2.188

4.  The cost effectiveness of treatment of genital warts with podophyllotoxin.

Authors:  K C Mohanty
Journal:  Int J STD AIDS       Date:  1994 Jul-Aug       Impact factor: 1.359

5.  Direct medical costs for surgical and medical treatment of condylomata acuminata.

Authors:  M Alam; M Stiller
Journal:  Arch Dermatol       Date:  2001-03

6.  Cutaneous cytodestructive potency of lignans. I. A comparative evaluation of influence on epidermal and dermal DNA synthesis and on dermal microcirculation in the hairless mouse.

Authors:  G von Krogh; H I Maibach
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

7.  An open, comparative, study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females.

Authors:  G R Kinghorn; A McMillan; F Mulcahy; S Drake; C Lacey; J S Bingham
Journal:  Int J STD AIDS       Date:  1993 Jul-Aug       Impact factor: 1.359

8.  Penile condylomata acuminata: an experimental model for evaluation of topical self-treatment with 0.5--1.0% ethanolic preparations of podophyllotoxin for three days.

Authors:  G von Krogh
Journal:  Sex Transm Dis       Date:  1981 Jul-Sep       Impact factor: 2.830

9.  Papillomavirus infection of the anogenital region: correlation between histology, clinical picture, and virus type. Proposal of a new nomenclature.

Authors:  G Gross; H Ikenberg; L Gissmann; M Hagedorn
Journal:  J Invest Dermatol       Date:  1985-08       Impact factor: 8.551

10.  An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle.

Authors:  R D Maw; M Reitano; M Roy
Journal:  Int J STD AIDS       Date:  1998-10       Impact factor: 1.359

View more
  19 in total

1.  Genital warts: a comprehensive review.

Authors:  Valerie R Yanofsky; Rita V Patel; Gary Goldenberg
Journal:  J Clin Aesthet Dermatol       Date:  2012-06

Review 2.  [Use of phytopharmaceutical agents in dermatology. Indications, therapeutic approaches and side effects].

Authors:  S Meyer; T Vogt; M Landthaler; S Karrer
Journal:  Hautarzt       Date:  2005-05       Impact factor: 0.751

Review 3.  An armamentarium of wart treatments.

Authors:  Michelle M Lipke
Journal:  Clin Med Res       Date:  2006-12

Review 4.  Economic and humanistic burden of external genital warts.

Authors:  Adam J N Raymakers; Mohsen Sadatsafavi; Fawziah Marra; Carlo A Marra
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

Review 5.  Anogenital warts in pediatric population.

Authors:  Miguel Costa-Silva; Inês Fernandes; Acácio Gonçalves Rodrigues; Carmen Lisboa
Journal:  An Bras Dermatol       Date:  2017 Sep-Oct       Impact factor: 1.896

Review 6.  Warts (genital).

Authors:  Henry W Buck
Journal:  BMJ Clin Evid       Date:  2010-08-13

7.  Viral Venereal Diseases of the Skin.

Authors:  Theodora K Karagounis; Miriam K Pomeranz
Journal:  Am J Clin Dermatol       Date:  2021-05-18       Impact factor: 7.403

Review 8.  Warts (genital).

Authors:  Henry W Buck
Journal:  BMJ Clin Evid       Date:  2007-08-01

9.  Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.

Authors:  Richard Gilson; Diarmuid Nugent; Kate Bennett; Caroline J Doré; Macey L Murray; Jade Meadows; Lewis J Haddow; Charles Lacey; Frank Sandmann; Mark Jit; Kate Soldan; Michelle Tetlow; Emilia Caverly; Mayura Nathan; Andrew J Copas
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

10.  A clinical and pathological overview of vulvar condyloma acuminatum, intraepithelial neoplasia, and squamous cell carcinoma.

Authors:  Boris Léonard; Frederic Kridelka; Katty Delbecque; Frederic Goffin; Stéphanie Demoulin; Jean Doyen; Philippe Delvenne
Journal:  Biomed Res Int       Date:  2014-02-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.